Details

Autor(en) / Beteiligte

• Liang, C G
• Wang, X
• Liu, S H
• Shi, X F

Titel

Evaluation of the efficacy of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B combined with nonalcoholic fatty liver disease by high-sensitivity detection of HBV DNA levels

Ist Teil von

• Zhonghua gan zang bing za zhi, 2023-02, Vol.31 (2), p.113

Ort / Verlag

China

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• To observe the efficacy of tenofovir disoproxil fumarate (TDF) antiviral therapy in patients with chronic hepatitis B (CHB) combined with nonalcoholic fatty liver disease (NAFLD), so as to provide evidence-based evidence in these special populations. Data from 91 CHB cases who received TDF 300 mg/d antiviral therapy for 96 weeks were analyzed retrospectively. Among them, 43 cases with NAFLD were included in the study group, and 48 cases without NAFLD were included in the control group. The virological and biochemical responses of the two groups of patients at 12, 24, 48, and 96 weeks were compared. Among them, 69 patients underwent highly sensitive detection of HBV DNA. The t-test and (2) test were performed on the data. ALT normalization rate was lower in the study group (42%, 51%) at 12 and 24 weeks of treatment than that in the control group (69%, 79%), and the difference was statistically significant ( < 0.05). However, there was no statistically significant difference between the two groups at 48 and 96